BioNTech Results Presentation Deck

3 BNT311 (anti-PDL1-anti-4-1BB) Mode of action Constitutive PD-L1 blockade & Conditional 4-1BB agonism PDL1 Blockade 0.001 0.01 PD-L1 x 4-1 B B Anti-P D-L1 (parental). Tumor size (mm³) 15 1024 Antibody concentration (g/mL) 512- 256- 128- 64- 32- 16- 0.1 8. 4- T 0 1 10 100 Anti-PD-L1 O Isotype control 751 41BB Agonism 0.001 Preclinical antitumor activity beyond PD1/PDL1 blockade 0.01 PD-L1 x 4-1 BB Antibody concentration (pg/mL) HIN 10 20 30 days post tumor implantation 0.1 40 T ctrl PD-L1 x Control Control x 4-1 BB mbs-PD-L1x4-1BB mbs-PD-L1xctrl mbs-ctrlx4-1BB Clinical trial objectives 1 Evaluate safety, PK & mode of action Evaluate clinical activity in 2 ● ● 10 refractory, progressive tumors 10 insensitive tumor types Study design: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 (BNT311) IV once every 21 days in subjects with malignant solid tumors Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian and Cervical Cancer Enrollment: ~192 patients First Data expected in 2H 2020 *SITC 2018, Altintas et al BIONTECH

View entire presentation